Advanced search
Publication Cover
Hematology Volume 17, 2012 - Issue 2
Submit an article Journal homepage
1,014
Views
10
CrossRef citations to date
0
Altmetric
Acute Leukemia

CD20 expression in B-cell precursor acute lymphoblastic leukemia is common in Mexican patients and lacks a prognostic value

Manuel Solano-GenestaServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
,
Luz Tarín-ArzagaServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, MexicoCorrespondence[email protected]
,
Ileana Velasco-RuizServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
,
Julia A. Lutz-PresnoCentro de Hematología y Medicina InternaClinica RUIZ, Puebla, Pue, Mexico
,
Oscar González-LlanoServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
,
Consuelo Mancías-GuerraServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
,
Laura Rodríguez-RomoServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
,
Guillermo J. Ruiz-DelgadoCentro de Hematología y Medicina InternaClinica RUIZ, Puebla, Pue, Mexico;Laboratorios Clínicos de Pueblo, Clínica Ruiz, Pueblo, Mexico
,
Guillermo J. Ruiz-ArgüellesCentro de Hematología y Medicina InternaClinica RUIZ, Puebla, Pue, Mexico;Laboratorios Clínicos de Pueblo, Clínica Ruiz, Pueblo, Mexico
,
José Carlos Jaime-PérezServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
&
David Gómez-AlmaguerServicio de Hematología, Hospital Universitario, ‘Dr. José E. González’ Universidad Autónoma de Nuevo León, Monterrey, NL, Mexico
 show all
Pages 66-70 | Published online: 18 Jul 2013

References

  • Stock W, La M, Sanford B, Bloomfield CD, Vardiman JW, Gaynon P, et al. What determines the outcome for adolescents and young adults with acute lymphoblastic leukemia treated on a cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies. Blood. 2008;112:1646–54
  • Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Eng J Med. 2006;354:166–78.
  • Ruiz-Argüelles A, Rivadeneyra-Espinoza L, Duque RE, Orfao A. Report of the second Latin American Consensus Conference for flow cytometric immunophenotyping of hematological malignancies. Cytom (Commun Clin Cytom). 2005;70B:39–44.
  • Gökbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Ann Haematol. 2003;83:201–5.
  • Jeha S, Behm F, Pei D, Sandlund JT, Ribeiro RC, Razzouk BI, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006;108:3302–4.
  • Chang H, Jiang A, Brandwein J. Prognostic relevance of CD20 in adult B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95:1040–2.
  • Thomas DA, O'Brien S, Jorgensen JL, Cortes J, Faderl S, Garcia-Manero G, et al. Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia. Blood. 2009;113:6330–7.
  • Maury S, Huguet F, Leguay T, Lacombe F, Maynadie M, Giralt S, et al. Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. Haematologica. 2010;95(2):324–8.
  • Borowitz MJ, Shuster J, Carrol J, Nash M, Look T, Camitta B, et al. Prognostic significance of fluorescence intensity of surface maker expression in childhood B-precursor acute lymphoblastic leukemia. A pediatric oncology group study. Blood. 1997;89(11):3960–6.
  • Huguet F, Leguay T, Raffoux E, Thomas X, Beldjord K, Delabesse E, et al. Pediatric inspired therapy in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia: the GRAALL 2003 study. J Clin Oncol. 2009;27:911–8.
  • Hoelzer D, Ludwig WD, Thiel E, Gassmann W, Löffler H, Fonatsch C, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87:495–508.
  • Dworzak MN, Schumich A, Printz D, Pötschger U, Husak Z, Attarbaschi A, et al. CD20 up-regulation in pediatric B cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy. Blood. 2008;112:3982–8.
  • Ruiz-Argüelles GJ, Fernández-Lara D, Estrada-Gómez R, Manzano C, Ruiz-Delgado GJ, Perez-Romano B, et al. Minimal residual disease testing in acute leukemia by flow cytometry immunophenotyping: prognostic significance. Lab Hematol. 2007;13:22–6.
  • Ruiz-Delgado GJ, Macías-Gallardo J, Lutz-Presno JA, Montes-Montiel M, Ruiz-Argüelles G. Outcome of adults with acute lymphoblastic leukemia treated with a pediatric inspired therapy: a single institution experience. Leuk Lymphoma. 2011;52:314–6.
  • Borowitz MJ, Pullen DJ, Winick N, Martin PL, Bowman WP, Camitta B, et al. Comparison of diagnostic and relapse flow cytometry phenotypes in childhood acute lymphoblastic leukemia: implications for residual disease detection: a report from the childreńs oncology group. Clin Cytom. 2005;68B:18–24.
  • Gaipa G, Basso G, Aliprandi S, Migliavacca M, Vallinoto C, Maglia O, et al. Prednisone induces immunophenotypic modulation of CD10 and CD34 in nonapoptotic B-cell precursor acute lymphoblastic leukemia cells. Clini Cytom. 2008;74B:150–5.
  • Lia G, De Martinis M, Matutes E, Farahat N, Morilla R, Catovsky D, et al. Levels of expression of CD19 and CD20 in chronic B cell leukemias. J Clin Phathol. 1998;51:364–9.
  • Hoelzer D, Huettmann A, Kaul F, Irmer SI, Jaeckel NJ, Mohren M, et al. Immunochemotherapy with rituximab in adult CD20 B-precursor ALL improves molecular CR rate and outcome in standard risk (SR) as well as in high risk (HR) patients with SCT. Haematologica. 2009;94: Abstract 481, p. 195.
  • Thomas DA, Kantarjian HM, Faderl S, Wierda W, Cortes J, Burger JA, et al. Chemoimmunotherapy with a modified hyper-CVAD and rituximab regimen improves outcome for patients with de novo Philadelphia negative precursor B-cell acute lymphoblastic leukemia (ALL). Blood (ASH Annual Meeting Abstracts). 2009;114: Abstract 236, p. 836.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.